RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases


22 Aug 2022, 14:00

· Idefirix[®] (imlifidase) becomes the first and only product reimbursed for the desensitization of highly sensitized patients waiting for a kidney transplant in Poland
· Reimbursement follows the inclusion of Idefirix[®] on the shortlist for exceptional innovative treatments with special funding   
· The reimbursement decision provides highly sensitized patient…
10 Aug 2022, 08:00

· European guidelines target the management of highly sensitized kidney transplant patients (patients with human leukocyte antigen (HLA) antibodies)
· These guidelines provide a new clinical practice tool for healthcare professionals to help achieve the best possible outcomes for highly sensitized kidney patients 
· Hansa Biopharma sponsors desensitization works…
19 Jul 2022, 08:00 | Regulatory
•    Continued solid sales in Q2
•    Positive NICE recommendation obtained 
•    Completed enrollment in imlifidase Phase 2 program in AMR 
•    Peter Nicklin elected as new Chairman of the Board of Directors
18 Jul 2022, 21:00 | Regulatory
Proceeds will be mainly utilized to: 

· Further strengthen the Company’s position in kidney transplantation through the continued support of ongoing European commercial launch activities for Idefirix (imlifidase) and execution of the U.S. ConfIdeS trial of imlifidase, which is expected to support a potential Biologics License Application (BLA) submission to the U.S. Fo…
Load more

Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.